David P Rotella
My lab is investigating structure activity relationships in a natural product that has activity as an inhibitor of HSP90. HSP90 is a key chaperone protein that plays a role in apoptosis, protein trafficking and folding. Inhibitors have been shown to be useful in preclinical models of neuroprotection and cancer. We are working with scientists at the University of Rochester to study new compounds and investigate their activity.
Protein kinase inhibitors for parasitic diseases
Collaborative drug discovery research is being carried out with Professor John Siekierka and coworkers in his laboratory and with researchers at Celgene Incorporated. Colleagues in my lab are synthesizing new analogs of a lead structure as potential protein kinase inhibitors. These compounds are being evaluated in Professor Siekierka's lab for activity against the target kinase and against the parasite for activity. Scientists at Celgene carry out more detailed studies with selected new molecules to evaluate their drug like properties. Together the team hopes to be able to identify molecules suitable for testing in humans to treat parasitic diseases.